fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Semaglutide for prevention or cure of HFpEF?

Written by | 18 Oct 2023

The results of the STEP-HFpEF trial point towards routine use of GLP-1 agonists in heart failure but this has to be balanced against conflicting guidelines and cost pressures… read more.

How semaglutide impacts HFpEF

Written by | 17 Oct 2023

The results of the STEP-HFpEF trial showed statistically significant benefits “across the board” and these benefits were not due to weight loss alone, according to Vicky Ruszala, Specialist… read more.

Could semaglutide help obese patients with heart failure?

Written by | 16 Oct 2023

STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.

Making sense of GLP-1 agonists

Written by | 29 Sep 2023

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents… read more.

What does a consultant pharmacist in diabetes do?

Written by | 28 Sep 2023

The work of a consultant pharmacist in diabetes spans clinical duties and leadership tasks including education and mentoring. There are at present only three consultant pharmacists in diabetes… read more.

Should GLP-1 agonists should be used earlier in type 2 diabetes?

Written by | 27 Sep 2023

In the future, GLP-1 agonists could be used early in treatment for type II diabetes and this could have an important impact on slowing the onset of complications,… read more.

How GLP-1 agonists help in type 2 diabetes

Written by | 26 Sep 2023

GLP-1 agonists such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents are now… read more.

Removing incorrect penicillin allergy labels in a UK hospital

Written by | 25 Aug 2023

Incorrect penicillin allergy labels can result in patients receiving less effective or more toxic antimicrobial agents but a pilot study has shown that a pharmacy-led multidisciplinary team can… read more.

Outcomes of penicillin allergy de-labelling

Written by | 24 Aug 2023

A total of 56 patients were successfully de-labelled in the pilot study but a key challenge will be preventing the erroneous reappearance of the penicillin allergy label, according… read more.

Why should we de-label ‘penicillin-allergic’ patients?

Written by | 23 Aug 2023

Incorrect penicillin allergy labels can result in patients receiving less effective or more toxic antimicrobial agents but a recent publication has shown that a pharmacy-led multidisciplinary team can… read more.

The European Society for Clinical Pharmacy (ESCP) – developments and aspirations

Written by | 14 Aug 2023

‘Innovations in Clinical Pharmacy Practice, Education and Research’ will be the topic of the forthcoming ESCP Symposium, to be held in Aberdeen, Scotland in Autumn 2023.  In this… read more.

How the Oath to Society underpins clinical pharmacy practice

Written by | 13 Aug 2023

The Oath to Society, jointly developed by ESCP and EAHP underpins clinical pharmacy services and highlights pharmacists’ work to those outside the profession, according to ESCP President, Professor… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.